Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Infliximab for the Prevention of Acute Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

NCT00201799 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT00201799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00201799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Infliximab for the Prevention of Acute Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
March 31, 2008
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease